34,050 Shares in ImmunityBio, Inc. (NASDAQ:IBRX) Acquired by Stratos Wealth Partners LTD.

Stratos Wealth Partners LTD. acquired a new position in ImmunityBio, Inc. (NASDAQ:IBRX) in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 34,050 shares of the company’s stock, valued at approximately $171,000.

Other hedge funds also recently added to or reduced their stakes in the company. Vanguard Group Inc. grew its holdings in shares of ImmunityBio by 42.0% during the 3rd quarter. Vanguard Group Inc. now owns 14,675,687 shares of the company’s stock worth $24,802,000 after purchasing an additional 4,342,386 shares during the period. Armistice Capital LLC purchased a new position in shares of ImmunityBio during the 3rd quarter worth $5,874,000. SG Americas Securities LLC grew its holdings in shares of ImmunityBio by 45.4% during the 4th quarter. SG Americas Securities LLC now owns 49,005 shares of the company’s stock worth $246,000 after purchasing an additional 15,308 shares during the period. Exchange Traded Concepts LLC grew its holdings in shares of ImmunityBio by 22.3% during the 3rd quarter. Exchange Traded Concepts LLC now owns 58,136 shares of the company’s stock worth $98,000 after purchasing an additional 10,596 shares during the period. Finally, Blair William & Co. IL grew its holdings in shares of ImmunityBio by 200.7% during the 3rd quarter. Blair William & Co. IL now owns 162,462 shares of the company’s stock worth $275,000 after purchasing an additional 108,431 shares during the period. 8.58% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Separately, Piper Sandler increased their price target on ImmunityBio from $4.00 to $5.00 and gave the stock a “neutral” rating in a report on Monday, March 25th.

ImmunityBio Trading Down 6.1 %

NASDAQ IBRX opened at $4.92 on Wednesday. The stock has a market cap of $3.33 billion, a PE ratio of -4.24 and a beta of 1.23. ImmunityBio, Inc. has a twelve month low of $1.25 and a twelve month high of $6.93. The stock has a fifty day simple moving average of $5.11 and a 200-day simple moving average of $4.01.

ImmunityBio (NASDAQ:IBRX) last announced its earnings results on Tuesday, March 19th. The company reported ($0.19) EPS for the quarter, missing analysts’ consensus estimates of ($0.18) by ($0.01). The company had revenue of $0.14 million during the quarter, compared to the consensus estimate of $0.03 million. Research analysts predict that ImmunityBio, Inc. will post -0.68 EPS for the current year.

ImmunityBio Company Profile

ImmunityBio, Inc, a clinical-stage biotechnology company, engages in discovering, developing, and commercializing next-generation immuno- and cellular therapies for cancer and infectious diseases in the United States and Europe. The company offers immunotherapy and cell therapy platforms, including antibody cytokine fusion protein N-803, vaccine delivery technologies, and natural killer cell therapies.